Videos and Podcasts
Pharmaxis CEO Gary Phillips details world-first clinical trial of treatment to prevent wound and burn scars
Pharmaxis Ltd CEO Gary Phillips speaks to Proactive's Andrew Scott soon after announcing they've entered a world-first clinical trial aiming to stop scars forming after trauma - particularly following burn injuries. Distinguished surgeon and burns expert Professor Fiona Wood AM is leading a group of researchers from the University of Western Australia (UWA) and Fiona Stanley Hospital to test the treatment in the first human trials.
Watch the interview here.
Pharmaxis enrols first patient in its bone marrow cancer trial
Pharmaxis Ltd CEO Gary Phillips discusses with Proactive's Andrew Scott the news they've enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis. The trial aims to demonstrate that PXS‐5505, the lead asset in Pharmaxis’ drug discovery pipeline, is safe and effective as a monotherapy in myelofibrosis patients, who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.
Watch the interview here.
Pharmaxis begins exporting its cystic fibrosis drug Bronchitol® to the USA
Pharmaxis CEO Gary Phillips speaks to Proactive Investor's Andrew Scott following the news Pharmaxis has exported the first shipment of its locally developed and manufactured drug Bronchitol® to the USA. Mr Phillips describes it as a proud and very rare achievement for a home‐ grown pharmaceutical research company. Watch the interview here.